Maria Cristina JanuÃ;rio Santos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/192321/publications.pdf

Version: 2024-02-01

46 papers 1,305 citations

430754 18 h-index 35 g-index

47 all docs

47 docs citations

47 times ranked

2110 citing authors

#	Article	IF	Citations
1	Cognition, function and awareness of disease impact in early Parkinson's and Huntington's disease. Disability and Rehabilitation, 2022, 44, 920-938.	0.9	5
2	Hereditary spastic paraparesis: The real-world experience from a Neurogenetics outpatient clinic. European Journal of Medical Genetics, 2022, 65, 104430.	0.7	4
3	Classification of Huntington's Disease Stage with Features Derived from Structural and Diffusion-Weighted Imaging. Journal of Personalized Medicine, 2022, 12, 704.	1.1	2
4	Tau and neurofilament lightâ€chain as fluid biomarkers in spinocerebellar ataxia type 3. European Journal of Neurology, 2022, 29, 2439-2452.	1.7	25
5	A link between synaptic plasticity and reorganization of brain activity in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	7
6	Automatic classification of idiopathic Parkinson's disease and atypical Parkinsonian syndromes combining [¹¹ C]raclopride PET uptake and MRI grey matter morphometry. Journal of Neural Engineering, 2021, 18, 046037.	1.8	15
7	Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3. Science Translational Medicine, 2020, 12, .	5.8	32
8	Protocol for the Characterization of the Cytosine-Adenine-Guanine Tract and Flanking Polymorphisms in Machado-Joseph Disease. Journal of Molecular Diagnostics, 2020, 22, 782-793.	1.2	1
9	The effect of impulsivity and inhibitory control deficits in the saccadic behavior of premanifest Huntington's disease individuals. Orphanet Journal of Rare Diseases, 2019, 14, 246.	1.2	7
10	Retinal texture biomarkers may help to discriminate between Alzheimer's, Parkinson's, and healthy controls. PLoS ONE, 2019, 14, e0218826.	1.1	54
11	A Novel Ecological Approach Reveals Early Executive Function Impairments in Huntington's Disease. Frontiers in Psychology, 2019, 10, 585.	1.1	12
12	Impulsivity across reactive, proactive and cognitive domains in Parkinson's disease on dopaminergic medication: Evidence for multiple domain impairment. PLoS ONE, 2019, 14, e0210880.	1.1	8
13	Clinical Features of Machado-Joseph Disease. Advances in Experimental Medicine and Biology, 2018, 1049, 255-273.	0.8	21
14	Visual and ocular motor function in the atypical form of neurodegeneration with brain iron accumulation type I. British Journal of Ophthalmology, 2018, 102, 102-108.	2.1	5
15	"Pinball―intrusions in spinocerebellar ataxia type 3. Neurology, 2018, 90, 36-37.	1.5	4
16	Parkinson's disease with hypocalcaemia: adult presentation of 22q11.2 deletion syndrome. BMJ Case Reports, 2018, 2018, bcr-2017-223751.	0.2	3
17	Reliability and Validity of 39-Item Parkinson's Disease Questionnaire and Parkinson's Disease Quality of Life Questionnaire. Acta Medica Portuguesa, 2017, 30, 395-401.	0.2	11
18	Parametric fMRI of paced motor responses uncovers novel wholeâ€brain imaging biomarkers in spinocerebellar ataxia type 3. Human Brain Mapping, 2016, 37, 3656-3668.	1.9	16

#	Article	IF	Citations
19	Transcranial Sonography and DaTSCAN in Early Stage Parkinson's Disease and Essential Tremor. European Neurology, 2016, 76, 252-255.	0.6	8
20	Tremor Frequency Assessment by iPhone \hat{A}^{\otimes} Applications: Correlation with EMG Analysis. Journal of Parkinson's Disease, 2016, 6, 717-721.	1.5	15
21	Substantia nigra hyperechogenicity does not correlate with motor features in Parkinson's disease. Journal of the Neurological Sciences, 2016, 364, 9-11.	0.3	9
22	Cognition and meaning. Medical Hypotheses, 2016, 94, 57.	0.8	0
23	Fibroblasts of Machado Joseph Disease patients reveal autophagy impairment. Scientific Reports, 2016, 6, 28220.	1.6	68
24	Classification of Huntington's disease stage with support vector machines: A study on oculomotor performance. Behavior Research Methods, 2016, 48, 1667-1677.	2.3	14
25	The concept of meaning: The key to clarify the human cognition and psychopathology. Medical Hypotheses, 2015, 84, 268-272.	0.8	5
26	The Impact of Mitochondrial Fusion and Fission Modulation in Sporadic Parkinson's Disease. Molecular Neurobiology, 2015, 52, 573-586.	1.9	79
27	The Upshot of LRRK2 Inhibition to Parkinson's Disease Paradigm. Molecular Neurobiology, 2015, 52, 1804-1820.	1.9	25
28	Mitochondrial respiratory chain complex activity and bioenergetic alterations in human platelets derived from pre-symptomatic and symptomatic Huntington's disease carriers. Mitochondrion, 2013, 13, 801-809.	1.6	39
29	Tremor modulations across periods with and without voluntary motion and limb load task demands using movement quantification., 2013, 2013, 4338-41.		2
30	Implicit Contextual Learning in Prodromal and Early Stage Huntington's Disease Patients. Journal of the International Neuropsychological Society, 2012, 18, 689-696.	1.2	13
31	Ubiquitin proteasome system in Parkinson's disease: A keeper or a witness?. Experimental Neurology, 2012, 238, 89-99.	2.0	37
32	Scanning Patterns of Faces do not Explain Impaired Emotion Recognition in Huntington Disease: Evidence for a High Level Mechanism. Frontiers in Psychology, 2012, 3, 31.	1.1	18
33	Posterior reversible encephalopathy syndrome: the importance of early diagnosis. BMJ Case Reports, 2012, 2012, bcr2012006852-bcr2012006852.	0.2	4
34	Specific impairment of visual spatial covert attention mechanisms in Parkinson's disease. Neuropsychologia, 2011, 49, 34-42.	0.7	18
35	Bioenergetic dysfunction in Huntington's disease human cybrids. Experimental Neurology, 2011, 231, 127-134.	2.0	52
36	Mitochondrial-dependent apoptosis in Huntington's disease human cybrids. Experimental Neurology, 2010, 222, 243-255.	2.0	53

#	Article	IF	CITATIONS
37	Motion integration deficits are independent of magnocellular impairment in Parkinson's disease. Neuropsychologia, 2009, 47, 314-320.	0.7	28
38	The role of the basal ganglia in implicit contextual learning: A study of Parkinson's disease. Neuropsychologia, 2009, 47, 1269-1273.	0.7	36
39	Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal. Neurobiology of Aging, 2009, 30, 1515-1517.	1.5	97
40	Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2. BMC Neurology, 2008, 8, 1.	0.8	52
41	Mitochondrial function in Parkinson's disease cybrids containing an nt2 neuron-like nuclear background. Mitochondrion, 2008, 8, 219-228.	1.6	102
42	Evidence of apoptosis and mitochondrial abnormalities in peripheral blood cells of Huntington's disease patients. Biochemical and Biophysical Research Communications, 2008, 374, 599-603.	1.0	53
43	Specific retinotopically based magnocellular impairment in a patient with medial visual dorsal stream damage. Neuropsychologia, 2006, 44, 238-253.	0.7	22
44	G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort. Movement Disorders, 2005, 20, 1653-1655.	2.2	106
45	Independent patterns of damage within magno-, parvo- and koniocellular pathways in Parkinson's disease. Brain, 2005, 128, 2260-2271.	3.7	114
46	Parkinson's Disease and Mitochondrial DNA NADH Dehydrogenase Subunit 1 Nucleotides 3337–3340: Study in a Population from the Central Region of Portugal (Coimbra). European Neurology, 2003, 50, 60-61.	0.6	3